Cart
sales@molnova.com
BCR-ABL-IN-7
CAS No. 688050-42-2
BCR-ABL-IN-7( —— )
Catalog No. M36483 CAS No. 688050-42-2
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 29 | In Stock |
|
| 10MG | 39 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 50MG | 84 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBCR-ABL-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
-
DescriptionBCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorBcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number688050-42-2
-
Formula Weight385.41
-
Molecular FormulaC19H16FN3O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N)(=O)C=1C2=C(SC1NC(=O)C=3C=C(ON3)C4=CC=C(F)C=C4)CCCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cao R, et al. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules. J Chem Inf Model. 2015 Nov 23;55(11):2435-42.?
molnova catalog
related products
-
Adaphostin
Adaphostin is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.
-
Nilotinib monohydroc...
A potent, selective, orally available inhibitor of both native and mutant Bcr-Abl with IC50 of 20-80 nM.
-
CHMFL-ABL-039
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia.
